Abstract
There is a lack of consensus regarding the treatment of inflammatory bowel disease after liver transplantation [LT],1 although some LT patients have responded favourably and safely to biologic therapies such as anti-tumour necrosis factor [TNF] therapy and vedolizumab.2–4 Recently tofacitinib, an oral small molecule Janus kinase [JAK] inhibitor, was shown to have potential efficacy as induction and maintenance therapy for moderately to severely active ulcerative colitis [UC].5 However, to our knowledge, there are no published data on the safety and efficacy of using tofacitinib in the management of active UC in LT recipients.